Literature DB >> 15812158

(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?

Markus Moehler1, Carl C Schimanski, Ines Gockel, Theodor Junginger, Peter R Galle.   

Abstract

Despite surgical R0 resections, patients with gastric cancer stage UICC II-III have a high risk of recurrence and metachronic metastases. Preliminary evidence exists that adjuvant chemotherapy or neoadjuvant chemo(radio)therapy protocols may improve the prognosis of these patients undergoing surgery of gastric cancer with curative intention. As for palliative regimens, 5-fluorouracil and cisplatin are integral components of such (neo)adjuvant strategies. Upcoming cytostatic agents, i.e. irinotecan, docetaxel, oxaliplatin, and oral fluoropyridines are currently under investigation in new multimodality treatment regimens and may further increase R0 resection rates and may prolong disease-free and overall survival in the treatment of advanced localized gastric cancer. Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh：

Year:  2004        PMID： 15812158     DOI： 10.1159/000083597

Source DB:  PubMed          Journal:  Dig Dis        ISSN： 0257-2753            Impact factor:   2.404


  8 in total

1.  Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.

Authors:  Yanlei Ma; Huanlong Qin; Qi Zheng; Yu Wang; Zhiguo Wang; Zhe Yang
Journal:  Med Oncol       Date:  2009-11-03       Impact factor: 3.064

2.  Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?

Authors:  Daniel Drescher; Markus Moehler; Ines Gockel; Kirsten Frerichs; Annett Müller; Friedrich Dünschede; Thomas Borschitz; Stefan Biesterfeld; Martin Holtmann; Thomas Wehler; Andreas Teufel; Kerstin Herzer; Thomas Fischer; Martin R Berger; Theodor Junginger; Peter R Galle; Carl C Schimanski
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 3.  Multidisciplinary management of gastric and gastroesophageal cancers.

Authors:  Markus Moehler; Orestis Lyros; Ines Gockel; Peter-R Galle; Hauke Lang
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

4.  Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome.

Authors:  Andreas-Claudius Hoffmann; Daniel Vallböhmer; Klaus Prenzel; Ralf Metzger; Michaela Heitmann; Susanne Neiss; Fredericke Ling; Arnulf H Hölscher; Paul M Schneider; Jan Brabender
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-04       Impact factor: 4.553

5.  Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.

Authors:  Zhipeng Sun; Nengwei Zhang
Journal:  World J Surg Oncol       Date:  2014-12-29       Impact factor: 2.754

Review 6.  Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives.

Authors:  Yasushi Sato; Koichi Okamoto; Tomoyuki Kawaguchi; Fumika Nakamura; Hiroshi Miyamoto; Tetsuji Takayama
Journal:  Biomedicines       Date:  2022-07-06

7.  Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.

Authors:  Markus Moehler; Ines Gockel; Hans-Peter Roessler; Dirk Arnold; Tanja Trarbach; Thomas Thomaidis; Gunther Klautke; Claus Rödel; Baruch Brenner; Hauke Lang; Peter R Galle; Carl C Schimanski; Heinz Schmidberger
Journal:  BMC Cancer       Date:  2013-02-11       Impact factor: 4.430

8.  Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases.

Authors:  Alexander Desuki; Frank Staib; Ines Gockel; Markus Moehler; Hauke Lang; Stefan Biesterfeld; Annett Maderer; Peter R Galle; Martin R Berger; Carl C Schimanski
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.